Search company, investor...

Founded Year

2016

Stage

Series B - II | Alive

Total Raised

$72.22M

Last Raised

$41.26M | 3 mos ago

About HSCSCI

HSCSCI integrates research, development, production, and sales of a new biomedical system. It focuses on the development of low-reagent consumption automatic genotyping, automatic fluid workstations, and other equipment. The company was founded in 2016 and is based in Chengdu, China.

Headquarters Location

No. 17, Huigu West Second Road Building H2, Tianfu International Biological City

Chengdu, Sichuan,

China

028-60656065

Loading...

Loading...

Latest HSCSCI News

China's HC Scientific gets $41m Series B extension

Aug 29, 2023

Send to Lake Bleu Capital and Guotai Junan Innovation Investment have led a Series B extension of approximately CNY 300m (USD 41m) for HC Scientific, a manufacturer of DNA sequencing devices used in modern agriculture and healthcare. Dalton Venture, Eightfold Venture Partners, and Guosheng Capital came in as new investors, while there were re-ups from Legend Capital and Lyfe Capital. It takes the overall Series B to around CNY 500m,... To continue reading...

HSCSCI Frequently Asked Questions (FAQ)

  • When was HSCSCI founded?

    HSCSCI was founded in 2016.

  • Where is HSCSCI's headquarters?

    HSCSCI's headquarters is located at No. 17, Huigu West Second Road, Chengdu.

  • What is HSCSCI's latest funding round?

    HSCSCI's latest funding round is Series B - II.

  • How much did HSCSCI raise?

    HSCSCI raised a total of $72.22M.

  • Who are the investors of HSCSCI?

    Investors of HSCSCI include LYFE Capital, Legend Capital, GTJA Innovation Investment, Dalton Venture, Lake Bleu Capital and 10 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.